Agenus Inc. – “Are We Getting Closer to Curing Cancer With Checkpoint Antibodies?”admin
By Market Exclusive Agenus Inc. (Nasdaq: AGEN) today
published a new blog post on The Chairman’s Blog, written by the
company’s Chairman and CEO, Dr. Garo Armen. TheChairmansBlog.com is
an exclusive online media publication that provides key executive
officers and key opinion leaders a unique platform to share insights
about company and industry trends.
Chairman and CEO, Dr. Garo Armen, discusses the company’s recently
announced definitive agreement to acquire 4-Antibody and the
potential he sees in checkpoint antibodies in the immunotherapy
market. Read the full blog post on TheChairmansBlog.com
Agenus Inc. is a biotechnology company
working to develop treatments for cancers and infectious diseases.
The company is focused on immunotherapeutic products based on strong
platform technologies with multiple product candidates advancing
through the clinic, including several product candidates that have
advanced into late-stage clinical trials through corporate partners.
For more information, please visit http://www.agenusbio.com/.
TheChairmansBlog.com is an exclusive,
online media publication where publically and privatively held firms
alike share insights about their companies and industries.
TheChairmansBlog.com enables upper tier management to discuss issues
that are of importance to their stakeholders, shareholders, and
interested parties in an informal environment. In addition to
management`s insightful blog posts, TheChairmansBlog.com staff and
aggregate partners contribute articles on finance, technology,
health, and energy while providing updated market trends, news, and
Posted: January 14th, 2014 under ACCESSWIRE.